ORIZURU THERAPEUTICS INC.: Regenerative Medicine and Drug Discovery using iPS technology

Top 5 Biotech Startups in Singapore – 2022

Currently, biotechnology startups place a greater emphasis on automation and computer-aided drug development. The most recent industry trends include the incorporation of AI, the development of personalized medicine, an increase in digital diagnosis, and a greater emphasis on immune cell functions.

The global Biotechnology services market was estimated at US$ 129.15 billion in 2021 and has grown at a compound annual growth rate (CAGR) of 15.6% to US$ 149.32. These trends have contributed to the potential for a sizable market for companies to invest further in the biotechnology startup sector.

This issue of Startup City features the ‘Top 5 Biotech startups in Japan - 2022’ which highlights some of the most important developments in the Japanese biotechnology space, as well as how biotechnology startups are operating in the current business environment and how they improve productivity and profitability.

The edition also includes a list of the ‘Top 10 Biotech Startups in APAC,’ highlighting the trends and developments in biotechnology startups throughout the Asia-Pacific region.

Furthermore, it includes the ‘Top 5 Biotech Startups in Singapore - 2022’ and ‘Top 5 Biotech Startups in South Korea - 2022’ which go into greater detail about the characteristics, trends, and developments of biotechnology startups in the respective regions.

It includes companies such as Orizuru Therapeutics, which was founded in 2021 as collaboration between Kyoto University and Takeda Pharmaceutical Company to research and commercialize iPS cell-based medicines. It is primarily concerned with cell regeneration therapy, regenerative medicine products derived from cell transplantation, and medication development.

The magazine also highlights the opinions of Michael Krel, Partner, Industrial Biotech Strategy, Sofinnova Partners, and Dr. Dan Liu, Partner in Venture and Growth Capital, CDH Investments. They respectively discuss the biotechnology industry’s evolution, challenges, and future, as well as how the industry is shaping up in China’s currently volatile business environment.

Write to us about how Biotechnology has assisted in the functioning of your organizations!

    Top Biotech Startups in Singapore

    Axcynsis Therapeutics Pte Ltd, a platform-based biotechnology company focusing on developing Antibody-X Conjugate (AXC) therapies, aims to transform cancer treatments. Leveraging proprietary technologies, the company is developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options. ... read full profile
    PVP Labs
    PVP Labs has always been on a mission to develop innovative drugs with the potential to make a world of difference in the healthcare space, pain management in particular. Adhering to this goal, the biotech-savvy team at PVP Labs has been conducting extensive research on peptide-based pain management since 2010
    ImmunoScape
    ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumor
    Nuevocor
    Headquartered in Singapore, Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts
    PairX Bio Pte. Ltd.
    PairX Bio Pte. Ltd. is developing next generation cancer immunotherapies targeting shared tumour-associated antigens derived from aberrantly spliced proteins. The PairX platform is built upon a deep understanding of mRNA splicing biology, which when combined with humans proprietary antigen and T cell validation methods yield simultaneous validation of tumour antigen-T cell pairs in multiple patient derived tumours